Skip to main content

Cytokine Release Syndrome

4
Pipeline Programs
6
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Incyte
IncyteDE - Wilmington
1 program
1
ItacitinibPhase 2Small Molecule1 trial
Active Trials
NCT04071366Completed112Est. Aug 2023
CytoAgents
CytoAgentsPA - Pittsburgh
1 program
1
CTO1681 10 μgPhase 1/21 trial
Active Trials
NCT05905328Recruiting54Est. Jun 2027
Noveome Biotherapeutics
1 program
1
ST266Phase 1
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ST266Phase 1
CytoSorbents
CytoSorbentsPRINCETON, NJ
1 program
CytosorbN/A1 trial
Active Trials
NCT04048434Unknown34Est. Sep 2024
IQVIA
IQVIADURHAM, NC
1 program
ST266PHASE_11 trial
Active Trials
NCT04720378Completed12Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IncyteItacitinib
CytoAgentsCTO1681 10 μg
IQVIAST266
CytoSorbentsCytosorb

Clinical Trials (4)

Total enrollment: 212 patients across 4 trials

NCT04071366IncyteItacitinib

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Start: Feb 2020Est. completion: Aug 2023112 patients
Phase 2Completed
NCT05905328CytoAgentsCTO1681 10 μg

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Start: Dec 2023Est. completion: Jun 202754 patients
Phase 1/2Recruiting
NCT04720378IQVIAST266

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Start: May 2021Est. completion: May 202212 patients
Phase 1Completed
NCT04048434CytoSorbentsCytosorb

Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

Start: Jun 2021Est. completion: Sep 202434 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 212 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.